GSC
TEVA icon

Grey Street Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Grey Street Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.85M Sell
130,954
-46
-0% -$580 0.25% 87
2023
Q4 		$1.37M Hold
131,000
– – 0.65% 39
2023
Q3 		$1.34M Hold
131,000
– – 0.77% 36
2023
Q2 		$986K Hold
131,000
– – 0.52% 44
2023
Q1 		$1.16M Buy
+131,000
New +$1.3M 0.82% 40

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Grey Street Capital's TEVA Position: Q1 2024 in Review

Grey Street Capital reduced its Teva Pharmaceuticals (TEVA) stake by 0.04% in Q1 2024, selling an estimated $580 and leaving 130,954 shares worth $1.85M. The position accounts for 0.25% of the portfolio, ranked #87.

Grey Street Capital first reported a position in TEVA in Q1 2023 and has held it in 5 quarters since. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Grey Street Capital held 130,954 shares of Teva Pharmaceuticals worth $1.85M as of Q1 2024.
  • Grey Street Capital sold 46 Teva Pharmaceuticals shares in Q1 2024, an estimated $580.
  • Teva Pharmaceuticals made up 0.25% of Grey Street Capital's portfolio in Q1 2024, its #87 holding.
  • Grey Street Capital first reported a position in Teva Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.